Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
05/2003
05/22/2003US20030096758 Anticarcinogenic agents
05/22/2003US20030096756 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/22/2003US20030096754 Vascular endothelial growth factor variants
05/22/2003US20030096739 Nuclear receptor-mediated introduction of a PNA into cell nuclei
05/22/2003US20030096737 Caspase inhibitors and uses thereof
05/22/2003US20030096705 Antagonists of MCP-1 function and methods of use thereof
05/22/2003US20030096370 Gram negative bacterial protein for use in the prevention and treatment of bacterial infection
05/22/2003US20030096350 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/22/2003US20030096338 Protein conjugate for use in the treatment of blood disorder
05/22/2003US20030096312 Novel natrium-calcium exchanger protein
05/22/2003US20030096299 Natural ligand of G protein coupled receptor ChemR23 and uses thereof
05/22/2003US20030096297 Method for identifying inhibitors of G protein coupled receptor signaling
05/22/2003US20030096022 Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
05/22/2003US20030096012 Film-forming powder, compositions containing it, methods for their preparation and their uses
05/22/2003US20030095992 Altering a drug's distribution, metabolism and elimination properties, especially by modifying with aralkyl ester moieties to increase rate of metabolism to inactive and nontoxic metabolites when exposure is halted; surgery, riots
05/22/2003US20030095973 Chlamydia antigens and corresponding DNA fragments and uses thereof
05/22/2003US20030095954 Growth factor gene fused with secretory signal sequence is introduced into fibroblasts ex-vivo using adenovirus vector; infecting cultured non-hematocytes with the vector; administering the cells
05/22/2003CA2756866A1 A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
05/22/2003CA2477642A1 Formoterol tartrate process and polymorph
05/22/2003CA2472019A1 Production of cell suspensions
05/22/2003CA2468497A1 Heterocyclic derivatives of glycinamide and their medical use
05/22/2003CA2467347A1 Histamine receptor h3 polynucleotides
05/22/2003CA2467267A1 Phenyl substituted triazoles and their use as selective inhibors of akl5 kinase
05/22/2003CA2467229A1 Dexrazoxane for treating antitumor-induced cardiotoxicity
05/22/2003CA2467081A1 Pyrazole derivatives as psychopharmaceuticals
05/22/2003CA2466962A1 Aryl aniline beta-2 adrenergic receptor agonists
05/22/2003CA2466632A1 Injectable depot compositions and uses thereof
05/22/2003CA2466519A1 Method for treating autoimmune diseases
05/22/2003CA2466465A1 Nk1 antagonists
05/22/2003CA2466440A1 Cannabinoid receptor ligands
05/22/2003CA2466422A1 Methods and compositions for use of (s)-bisoprolol
05/22/2003CA2466415A1 Pgc-1.beta., a novel pgc-1 homologue and uses therefor
05/22/2003CA2466355A1 Neurotransmitter balance chemotherapy
05/22/2003CA2465893A1 Polycyclic guanine derivative phosphodiesterase v inhibitors
05/22/2003CA2465868A1 A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
05/22/2003CA2465861A1 Carboxylic acid derivative compounds and drugs containing the same as the active ingredient
05/22/2003CA2465776A1 Use of specific dose of fondaparinux sodium for the treatment of acs
05/22/2003CA2464863A1 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation
05/22/2003CA2464861A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
05/22/2003CA2464347A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
05/22/2003CA2460959A1 Enzymes
05/21/2003EP1312920A1 Method of screening remedy for heart failure
05/21/2003EP1312601A1 Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient
05/21/2003EP1312379A1 Fibrinogen lowering agents
05/21/2003EP1312376A1 Vascular relaxation agents
05/21/2003EP1312369A1 Cardiac arrest fluid
05/21/2003EP1312367A1 Heterocyclo-alkylsulfonyl pyrazolesa and their use as COX-2 inhibitors
05/21/2003EP1312356A1 Aqueous suspension preparations
05/21/2003EP1311708A1 Method for identifying substances useful for treating inflammation using the response element to the ikappabaplha ror receptor
05/21/2003EP1311704A2 Novel target genes for diseases of the heart
05/21/2003EP1311699A2 Adeno-associated virus-mediated delivery of angiogenic factors
05/21/2003EP1311677A2 Regulation of human p2y1-like g protein-coupled receptor
05/21/2003EP1311666A2 Progression suppressed gene 13 (psgen 13) and uses thereof
05/21/2003EP1311547A2 Diagnosis and treatment of cardiovascular conditions
05/21/2003EP1311534A1 Thioether-sulphamate steroids as steroid sulphatase inhibitors and anti-cancer compounds
05/21/2003EP1311533A1 17-aryl-linker derivatised estrogen 3-sulphamates as inhibitors of steroid sulphatase
05/21/2003EP1311532A1 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase
05/21/2003EP1311525A2 Composition and method for inhibiting platelet aggregation
05/21/2003EP1311522A1 New immunoeffector compounds
05/21/2003EP1311507A1 Fused pyrazole derivatives being protein kinase inhibitors
05/21/2003EP1311503A1 Chromenone derivatives and their use for treating diseases in conjunction with 5-hta1 receptors and/or dopamine d2 receptors
05/21/2003EP1311501A1 Antithrombotic agents
05/21/2003EP1311500A2 Indole, azaindole and indazole derivatives having vegf inhibiting activity
05/21/2003EP1311499A2 Bicyclic compounds as h3 receptor ligands
05/21/2003EP1311489A1 Biphenyl derivatives and the use thereof as integrin inhibitors
05/21/2003EP1311488A1 Substituted imidazoles as tafia inhibitors
05/21/2003EP1311486A1 Uses of thaliporphine or its derivatives in treatment of cardiac diseases and preparation of same
05/21/2003EP1311485A1 Processes for preparing cilostazol
05/21/2003EP1311484A1 Biphenyl derivatives and the use thereof as integrin inhibitors
05/21/2003EP1311482A2 Non-imidazole aryloxypiperidines as h3 receptor ligands
05/21/2003EP1311480A1 New amidino derivatives and their use as thrombin inhibitors
05/21/2003EP1311478A1 Novel thiourea compounds and the pharmaceutical compositions containing the same
05/21/2003EP1311476A1 Aza-amino acid derivatives (factor x a?-inhibitors 15)
05/21/2003EP1311475A1 Novel aminocyclohexane derivatives
05/21/2003EP1311473A2 Novel compounds inhibiting factor xa activity
05/21/2003EP1311471A1 Phenyl- and phenylalkyl-substituted ethanolamines and ethylenediamines
05/21/2003EP1311302A2 Pharmaceuticals for the imaging of angiogenic disorders
05/21/2003EP1311298A2 System for regulating in vivo the expression of a transgene by conditional inhibition
05/21/2003EP1311297A1 A method for reducing stress-induced overproduction of neuropeptide y in an individual
05/21/2003EP1311295A2 Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation
05/21/2003EP1311284A2 Saratin for inhibiting platelet adhesion to collagen
05/21/2003EP1311282A1 High affinity integrin polypeptides and uses thereof
05/21/2003EP1311273A2 Combination of a purine and an nsaid for treating sexual dysfunction
05/21/2003EP1311270A1 Non-sedating barbiturate compounds as neuroprotective agents
05/21/2003EP1311263A2 Fused pyrrolocarbazoles against inflammation
05/21/2003EP1311258A2 Compositions containing hypotriglyceridemically active stilbenoids
05/21/2003EP1311255A1 Compounds having mif antagonist activity
05/21/2003EP1311252A2 Treatment of wounds
05/21/2003EP1311245A1 Hybrid neuroprosthesis for the treatment of brain disorders
05/21/2003EP1311239A1 Oral delivery of peptide
05/21/2003EP1263979A4 Method of purifying a fermentation broth
05/21/2003EP1192161B1 Chromeno[4,3,2-de]isoquinolines as potent dopamine receptor ligands
05/21/2003EP1144003A4 Methods and devices for delivery of agents to breast milk ducts
05/21/2003EP1131334A4 Use of core 2 glcnac transferase inhibitors in treating inflammation
05/21/2003EP1129096B1 Crf receptor antagonists and methods relating thereto
05/21/2003EP1115701B1 Arylsulfonanilide ureas
05/21/2003EP0411031B1 THE HUMAN C3b/C4b RECEPTOR (CR1)
05/21/2003CN1419563A Peptide derivative
05/21/2003CN1419559A Tricyclic protein kinase inhibitors
05/21/2003CN1419552A 2-amino-3-(alkyl)-pyrimidone derivatives as GSKS beta. inhibitors
1 ... 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 ... 1595